Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

New Tocilizumab (TCZ) Dosing Guidance for T-Cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Insights from Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses

Candice Jamois, David C. Turner, Leonid Gibiansky, Feifei Li, Nicolas Frey, Jean-Francois Menuet, Leonardo Roque Pereira, Linda Lundberg, Elena Guerini, David John Carlile, James Relf, Michael C. Wei, Antonia Kwan, Susan Grange

Blood (2023) 142 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2023-177679

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Matthew Matasar, Toby A. Eyre, Eva Gine, Audrey Filézac De L'Étang, Ben Byrne, Linda Lundberg, Alejandra Padovani, Christophe Boetsch, Alessia Bottos, Naseer Qayum

Blood (2023) 142 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2023-173946

Published: 2023

Journal Articles

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Blood (2022) 140 (Supplement 1): 1062–1064.

https://doi.org/10.1182/blood-2022-157554

Published: 2022

Journal Articles

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 178–180.

https://doi.org/10.1182/blood-2022-157777

Published: 2022

Journal Articles

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Michael Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Krish Patel, Cyrus Khan, Nancy L. Bartlett, Gloria Iacoboni, Mark Hertzberg, Sirpa Leppä, Eric Van Den Neste, Monica Tani, Guillaume Cartron, Antonio Salar, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings

Blood (2021) 138 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2021-146845

Published: 2021

Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood (2021) 138 (Supplement 1): 128.

https://doi.org/10.1182/blood-2021-148778

Published: 2021

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Nassim Djebli, Peter N Morcos, Félix Jaminion, Elena Guerini, Nicole A Kratochwil, Nicole Justies, Eginhard Schick, Antonia Kwan, Kathryn Humphrey, Linda Lundberg, David Carlile

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136311

Published: 2020

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Carmelo Carlo-Stella, MD, Emmanuel Bachy, MD PhD, Fritz C. Offner, MD PhD, Franck Morschhauser, MD PhD, Michael Crump, Gloria Iacoboni, MD, Anna Sureda Balari, MD PhD, Joaquin Martinez-Lopez, MD, Linda Lundberg, Mark Dixon, David Perez Callejo, James Relf, David Carlile, Emily Piccione, Kathryn Humphrey, Michael Dickinson, DMed Sci

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-136044

Published: 2020

NARROW

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only